SHANGHAI - China regulators released a streamlined draft drug approval rule this month that would provide for faster approval of four categories of new drugs. The State Food and Drug Administration finished collecting public comments on the rule Oct. 15
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
